Orion (OEC)

NYSE Market Open

Orion S.A. is a global producer of carbon black, a finely divided form of carbon used to change the strength, durability, conductivity, colour, and processing characteristics of industrial materials. The company supplies customers across automotive, tire, coatings, plastics, printing, battery, and other specialty markets, making it part of the chemical supply chain behind many everyday and industrial products.

Orion reports its business through two main segments: Rubber Carbon Black and Specialty Carbon Black. Rubber Carbon Black is the larger revenue contributor and is primarily used to reinforce tires and mechanical rubber goods, where it helps improve wear resistance, tensile strength, and overall performance. Demand in this segment is closely tied to tire production, vehicle use, replacement tire cycles, and broader industrial activity.

The Specialty Carbon Black segment serves higher-value applications where carbon black functions as a pigment or performance additive. These products are used in coatings, inks, polymers, cables, conductive compounds, and other applications that require specific colour, electrical, or technical properties. Specialty grades can be more customized than standard rubber grades, giving Orion exposure to markets where material performance is a key purchasing factor.

The company operates internationally, with a significant revenue base in Europe and particularly Germany, according to its reported geographic mix. Orion’s position is shaped by manufacturing scale, technical know-how, customer qualification requirements, and the need to meet environmental and quality standards in a heavily regulated chemicals industry.

7.22 USD
−0.04 (-0.62%)

Last updated

Market Cap
410.51M
P/E
P/FCF
11.7
P/S
0.23
Enterprise Value
1.37B
Sector
Industry
Address
1700 CITY PLAZA DRIVE, SUITE 300, SPRING, TX, 77389
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2026

Apr 23, 2026, 05:00 A.M.
GlobeNewswire Inc.

Gabelli Hosts 17th Annual Specialty Chemicals Symposium

Feb 24, 2026, 08:00 A.M.
GlobeNewswire Inc.

Orion Group Interim Report January–September 2025

Oct 28, 2025, 06:00 A.M.
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–syyskuu 2025

Oct 28, 2025, 06:00 A.M.
GlobeNewswire Inc.

Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025

Jul 18, 2025, 05:00 A.M.
GlobeNewswire Inc.

Sisäpiiritieto: Orion parantaa näkymäarviota vuodelle 2025

Jul 09, 2025, 06:00 A.M.
GlobeNewswire Inc.

Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien kehittämiseksi

Jun 17, 2025, 02:00 A.M.
GlobeNewswire Inc.

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

Jun 17, 2025, 02:00 A.M.
GlobeNewswire Inc.

Orionin yhteistyökumppani MSD laajentaa opevesostaatin kliinistä kehitysohjelmaa naisten syöpiin

May 21, 2025, 00:30 A.M.
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2025

Apr 23, 2025, 05:00 A.M.
GlobeNewswire Inc.

Lääketeollisuus luovutti hallitukselle arvolupauksen: miljarditason investoinnit vuoteen 2030 mennessä

Mar 21, 2025, 07:00 A.M.
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

Jan 07, 2025, 02:00 A.M.
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee Kiinassa kolmatta indikaatiota darolutamidille

Jan 07, 2025, 02:00 A.M.
GlobeNewswire Inc.

Orion ja Abilita Therapeutics sopivat tutkimusyhteistyöstä ja lisenssisopimusoptiosta innovatiivisten vasta-ainehoitojen kehittämiseksi

Dec 18, 2024, 10:00 A.M.
GlobeNewswire Inc.

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

Dec 18, 2024, 10:00 A.M.
GlobeNewswire Inc.

Sisäpiiritieto: Orion lopettaa ODM-111-kehitysohjelman perustuen molekyylin liian kapeaan terapeuttiseen ikkunaan

Oct 24, 2024, 12:50 P.M.
GlobeNewswire Inc.

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

Oct 24, 2024, 12:50 P.M.
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee EU:ssa kolmatta indikaatiota darolutamidille

Oct 14, 2024, 04:00 A.M.
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

Oct 14, 2024, 04:00 A.M.
GlobeNewswire Inc.

Darolutamidi yhdessä ADT-hoidon kanssa pienensi merkitsevästi (46 prosentilla) syövän etenemisen tai kuoleman riskiä verrattuna lumelääkkeen ja ADT:n yhdistelmään levinnyttä hormonisensitiivistä eturauhassyöpää sairastavilla potilailla

Sep 16, 2024, 04:30 A.M.
Market Cap
410.51M
Enterprise Value
1.37B
P/E
P/B
1.08
P/S
0.23
EV / EBITDA
6.49
EV / Sales
0.77
EPS
-1.58
Dividend Yield
1.14%
P/FCF
11.7
P/CF
2.02
Free Cash Flow
35.1M
ROE
-23.48%
ROA
-4.61%
Debt / Equity
2.67
Current Ratio
1
Quick Ratio
0.62
Cash
0.08
Avg Volume
460.37K
Fundamentals Snapshot Price
7.28

Income Statement

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Revenue 459.5M 411.7M 450.9M 466.4M 477.7M
Gross profit 79.2M 77.7M 85.6M 98.4M 98.1M
Operating income 11.4M 13.5M -52.3M 32.1M 31.2M
EBITDA 44.1M 41.3M 62.2M 64.1M 62.7M
Net income -9.9M -21.1M -67.1M 9M 9.1M
Basic EPS -0.18 -0.37 -1.2 0.16 0.16
Diluted EPS -0.18 -0.37 -1.2 0.16 0.16

Balance Sheet

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Total assets 1.93B 1.91B 1.96B 2.02B 1.97B
Total liabilities 1.55B 1.52B 1.56B 1.56B 1.5B
Total equity 379.5M 384.6M 401.8M 466.5M 466.1M
Cash & equivalents 50.5M 60.7M 51.3M 42.6M 37.5M
Current assets 661.5M 643.8M 683.5M 682.5M 688.6M
Current liabilities 659.7M 626.4M 635.3M 620.8M 601.9M

Cash Flow

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Operating cash flow -12.4M 92.9M 68.8M 53.7M 400K
Investing cash flow -36.1M -48.7M -40.9M -42.2M -29.2M
Financing cash flow 39.6M -35.7M -19.5M -7.8M 21.8M
Change in cash -8.9M 8.5M 8.4M 3.7M -7M
Kind Filing Date Link
edgar index 8-K — Orion S.A. View Filing
edgar index 10-Q — Orion S.A. View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
form 4 Form 4 — Niewiem Sandra View Filing
form 4 Form 4 — Painter Corning F. View Filing
form 4 Form 4 — Puckett Jonathan A. View Filing
form 4 Form 4 — Quinones Carlos View Filing
form 4 Form 4 — Riveros Pedro View Filing
edgar index ARS — Orion S.A. View Filing
edgar index DEF 14A — Orion S.A. View Filing
edgar index 8-K — Orion S.A. View Filing
eight k text 8-K — 8-K View Filing
edgar index PRE 14A — Orion S.A. View Filing
edgar index 8-K — Orion S.A. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Orion S.A. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Orion S.A. View Filing
edgar index SCHEDULE 13G — Orion S.A. View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
form 4 Form 4 — Niewiem Sandra View Filing
form 4 Form 4 — Niewiem Sandra View Filing
form 4 Form 4 — Niewiem Sandra View Filing
form 4 Form 4 — Painter Corning F. View Filing
form 4 Form 4 — Painter Corning F. View Filing
form 4 Form 4 — Painter Corning F. View Filing
form 4 Form 4 — Quinones Carlos View Filing
form 4 Form 4 — Quinones Carlos View Filing
form 4 Form 4 — Quinones Carlos View Filing
form 4 Form 4 — Riveros Pedro View Filing
form 4 Form 4 — Riveros Pedro View Filing
form 4 Form 4 — Riveros Pedro View Filing
edgar index 8-K — Orion S.A. View Filing
edgar index 10-K — Orion S.A. View Filing
eight k text 8-K — 8-K View Filing
ten k section 10-K — business View Filing
ten k section 10-K — mda View Filing
ten k section 10-K — risk_factors View Filing
edgar index 4 — Orion S.A. View Filing
form 4 Form 4 — Puckett Jonathan A. View Filing
edgar index 3 — Orion S.A. View Filing
edgar index 8-K — Orion S.A. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Orion S.A. View Filing
edgar index 10-Q — Orion S.A. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Orion S.A. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Orion S.A. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Orion S.A. View Filing
edgar index 8-K — Orion S.A. View Filing
edgar index 10-Q — Orion S.A. View Filing
edgar index SCHEDULE 13G/A — Orion S.A. View Filing
edgar index 8-K — Orion S.A. View Filing
edgar index SCHEDULE 13G/A — Orion S.A. View Filing
edgar index 3 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
edgar index 4 — Orion S.A. View Filing
form 4 Form 4 — GALVIN KERRY A View Filing